From the impact of Obamacare to cutting edge research, from biotech buyouts to big pharma court battles, the Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week's edition, the team talks about big pharma patent disputes, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.
The Motley Fool's chief investment officer has selected his No. 1 stock for this year. Find out which stock it is in the brand-new free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.